drugset / Trial / NCT00202800
Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
Completed
40 enrolled
Corewell Health West
Battle Creek Health System · collabEli Lilly and Company · collabMecosta County General Hospital · collabMercy Health System · collabMetropolitan Hospital, Michigan · collabMunson Medical Center · collabSaint Mary's Health Network · collabVan Andel Research Institute · collab
Non-randomizedSingle-groupSingle-blindTreatment
Summary
Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer.
Timeline
- Start
- 2002-03
- Primary completion
- 2007-09
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |